Emerald Clinical

What if your recruitment problem is actually a protocol problem? Complex eligibility criteria, burdensome procedures and competition for limited patient populations can undermine oncology trial recruitment before a study even begins. Rethinking Recruitment and Retention in Competitive Oncology Clinical Trials explores why feasibility needs to inform study design from day one. Claudio Hegenberger, MD and Johannes Wolff, MD, PhD share practical perspectives on patient access, KOL involvement, protocol complexity, country selection and retention and why these factors need to be considered together. Design for the patients and sites that exist in the real world, not just the ideal study population. Read the article - emeraldclinical.com/insights… #OncologyClinicalTrials #Oncology #ClinicalResearch #PatientRecruitment #Biotech

Why are more sponsors looking to China and APAC earlier? Dan Gallagher explains how growing competition for investigators, sites and patients is changing global development strategies, and why APAC is becoming an increasingly important consideration for sponsors seeking to accelerate clinical development. Read the article - emeraldclinical.com/insights… At Emerald Clinical Trials, our APAC heritage, deep China expertise and global capabilities help biotech and pharma sponsors turn that opportunity into an integrated development strategy. #ClinicalTrials #APAC #China #Biotech #Pharma #ClinicalDevelopment

Speed matters in oncology drug development. Bringing a new cancer therapy from concept to proof of concept has never been more challenging. Increasingly complex biologics, precision medicines, and cell therapies require smarter development strategies. An integrated development approach can: ✅ Reduce operational complexity ✅ Accelerate patient enrollment ✅ Enable faster dose and cohort decisions ✅ Shorten timelines to critical proof-of-concept milestones When science, strategy, and execution are aligned from the start, sponsors can make better decisions faster. Read our new thought leader article here by Luke Gill , and Dr Wang explain more -emeraldclinical.com/insights… #Oncology #ClinicalTrials #BiotechInnovation #DrugDevelopment #ClinicalOperations

Why do oncology trials struggle to recruit, even when the science is compelling? In their latest article, Claudio Hegenberger, MD and Johannes Wolff, MD, PhD explore why recruitment and retention challenges often start long before the first patient is enrolled. From overly complex protocols and narrow eligibility criteria to competition for the same patient populations, they examine how early feasibility, KOL engagement, smarter patient-access strategies and strategic country selection can help sponsors de-risk oncology studies. Recruitment isn’t just an operational challenge. It starts with how the study is designed. Read the full article - emeraldclinical.com/insights… #Oncology #ClinicalTrials #PatientRecruitment #ClinicalDevelopment #Biotech

APAC is no longer an afterthought in global clinical development. China and the broader APAC region are increasingly moving earlier into sponsors’ development strategies, driven by the need to accelerate timelines, access patients faster and unlock asset value earlier. As competition for sites, investigators and patients intensifies across the US and Europe, the question is shifting from “Should we include APAC?” to “How early should APAC be part of our global strategy?” In his latest article, Dan Gallagher explains why China and APAC are moving from an optional expansion geography to a strategic consideration in global clinical development, as sponsors look to access patients faster, accelerate timelines and compete more effectively for sites and investigators. Read more emeraldclinical.com/insights… At Emerald Clinical Trials, our APAC heritage, deep China expertise and global capabilities help biotech and pharma sponsors turn that opportunity into an integrated development strategy. #ClinicalTrials #APAC #China #Biotech #Pharma #ClinicalDevelopment

Renal innovation is accelerating. Is clinical development keeping pace? As kidney disease becomes more targeted and therapeutically diverse, sponsors need to bring together disease biology, patient selection, biomarkers, endpoints, clinical operations and evidence strategy earlier in development. Following ASN Kidney Week 2026, we look at five trends shaping the next generation of renal clinical development and the implications for biotech and pharma. Explore the five takeaways → emeraldclinical.com/insights… #RenalResearch #ClinicalDevelopment #Nephrology #Biotech #Pharma #ClinicalTrials

Is the traditional oncology development model slowing innovation? As cancer therapies become increasingly complex, many development programs still rely on fragmented study designs that add time, cost, and operational risk. Integrated proof-of-concept models can help sponsors move faster by combining early development stages, leveraging adaptive designs, and using seamless protocols to accelerate decision-making. The result? Faster insights, more efficient development pathways, and earlier confidence in promising therapies. At Emerald Clinical, we are helping sponsors rethink how oncology trials are designed to bring innovative treatments to patients sooner. Our Oncology experts , explain more -emeraldclinical.com/insights… #OncologyClinicalTrials #DrugDevelopment #ClinicalResearch #Biotech #ProofOfConcept

What if oncology proof of concept could be reached months sooner? The future of cancer drug development isn't just about better therapies. It's about smarter trial design. Integrated protocols, adaptive methodologies, and global execution strategies are helping sponsors accelerate timelines while maintaining scientific rigor. Because patients can't wait. Read our new thought leader article here -emeraldclinical.com/insights… #OncologyResearch #ClinicalTrials #Biotech #CancerResearch #DrugDevelopment #EmeraldClinical

Many sponsors still view China and Japan as regions to add later in development. However, data shared in our recent webinar suggests that incorporating these markets from the start can significantly improve enrolment certainty and accelerate timeline In our latest article, we explore; • How China and Japan can act as dual engines for global oncology development • Why protocol design is the critical moment to integrate APAC • Evolving regulatory pathways supporting multi-regional clinical trials • Strategies to accelerate proof-of-concept and reduce development risk For sponsors pursuing faster, more predictable oncology development, APAC is increasingly becoming a strategic advantage rather than a late-stage consideration. Read the article and discover how early APAC planning can help accelerate your next oncology program. emeraldclinical.com/insights… #Oncology #ClinicalTrials #DrugDevelopment #ClinicalResearch #APAC #ChinaClinicalTrials #JapanClinicalTrials #OncologyDevelopment #Biotech #EmeraldClinical #GlobalClinicalTrials

As we wrap up ASN Kidney Week 2026, we want to thank everyone who stopped by the Emerald Clinical booth, connected with our team, and shared insights on the future of nephrology research. A special thank you to everyone who met with our team and joined discussions with nephrologist Dr. Vanesa Pomeranz. We appreciate the opportunity to exchange ideas and explore new possibilities together. We leave ASN energized by the connections made and excited for what lies ahead. #ASNKidneyWeek #KidneyWeek2026 #Nephrology #ClinicalResearch #ClinicalTrials #EmeraldClinical #KidneyDiseaseResearch

We're onsite at ASN Kidney Week 2026 and looking forward to connecting with colleagues, sponsors, and partners from across the nephrology community. Our team is here to discuss how Emerald Clinical supports kidney disease research through global clinical development expertise, operational excellence, and access to diverse patient populations. 📍 Visit us at Booth 1039 to meet the team and learn how we can help advance your nephrology program. 🔗 Learn more or schedule a meeting: emeraldclinical.com/meet-us-… You can also meet nephrologist Dr. Vanesa Pomeranz at our booth on Thursday, October 22, and Friday, October 23, from 10:00 a.m. to 12:00 p.m. for discussions on advancing your nephrology clinical research initiatives. #ASNKidneyWeek #ASN2026 #Nephrology #KidneyDisease #ClinicalResearch #Biotech #Pharma #EmeraldClinical

When should Asia-Pacific enter your oncology clinical development strategy? For many biotechs planning proof-of-concept or pivotal oncology studies, development strategies naturally begin in the US and Europe. But as global oncology innovation continues to evolve, is it time to bring Asia-Pacific into the conversation earlier? In our latest video, Luke Gill, Vice President, Global Head of Oncology at Emerald Clinical, shares his perspective on why sponsors should be rethinking the timing of Asia-Pacific integration into their clinical development plans. With nearly 3,000 active Phase I-III oncology trials across the region, Asia-Pacific offers extensive infrastructure, experienced investigators, regulatory expertise, and access to diverse patient populations. As oncology drug development becomes increasingly global, clinical strategies should reflect that reality. 🎥 Watch the video to hear Luke's insights. 📍 Meet the Emerald Clinical team at ESMO 2026 Booth 1076A To learn more schedule a meeting: 🔗 emeraldclinical.com/meet-us-… #ESMO2026 #Oncology #ClinicalResearch #Biotech #CancerResearch #PrecisionMedicine #Emeraldclinical

Small cell lung cancer trials require focused oversight, proactive problem-solving, and strong collaboration across stakeholders. Our latest case study highlights how Emerald Clinical supported a complex SCLC trial through strategic project management and operational coordination. Read the full case study here emeraldclinical.com/insights…, then stop by our booth at ESMO to meet our team and learn how we can support your oncology development programs. Book time to meet with us now here emeraldclinical.com/meet-us-… or come by booth #1076A to talk about how we can get your Clinical Trial off the ground. #ESMO #LungCancerResearch #OncologyClinicalTrials #ClinicalResearch #EmeraldClinical

China's rich and diverse patient population continues to make it a key market for advancing kidney disease research. Yapeng Zhao, Senior Director, Head of Medical Affairs & Head of Drug Safety discusses her perspective on the evolving nephrology landscape, the opportunities for global development programs, and how regional expertise can help sponsors navigate clinical development with confidence. Meet the Emerald Clinical team at ASN Kidney Week, booth 1039. Contact us to arrange a meeting with our scientific renal experts emeraldclinical.com/meet-us-… #Nephrology #RenalResearch #ClinicalDevelopment #ASNKidneyWeek #ChinaClinicalTrials #EmeraldClinical

🌍 European Perspectives on Kidney Disease Innovation As the nephrology landscape continues to evolve, understanding regional insights and emerging approaches is critical to advancing patient care. In this video, Dr. Loreto Gesualdo, Full Professor of Nephrology shares his expert perspective on: ✅ European perspectives on kidney disease innovation ✅ Precision medicine in nephrology ✅ Emerging treatment paradigms Join Emerald Clinical at ASN Kidney Week 2026, October 22-24, to connect with our team and discuss the latest trends and opportunities shaping nephrology research and clinical development. 📍 Visit us at Booth #1039 📅 Schedule a meeting with our team: emeraldclinical.com/meet-us-… #ASNKidneyWeek2026 #KidneyDisease #PrecisionMedicine #ClinicalResearch #KidneyHealth #RenalResearch #EmeraldClinical

Complex protocol criteria. Hard-to-find patient cohorts. Strict stratification requirements. In rare renal diseases like IgA Nephropathy, FSGS, and C3G, finding the right patients is the ultimate bottleneck. Emerald Clinical delivers global patient access. Our established investigator networks unlock hard-to-find CKD and orphan renal populations, accelerating your enrollment timelines despite complex criteria. Let's optimize your trial execution. Meet our team at ASN at Booth #1039. Set up a time today - emeraldclinical.com/meet-us-… On Thursday, October 22, and Friday, October 23, from 10:00 a.m. to 12:00 p.m., nephrologist Dr. Vanesa Pomeranz will be available at our booth for consultation and discussions on advancing your nephrology clinical research programs. #KidneyWk #ASNKidneyWeek2026 #ImprovingLivesWorldwide #ClinicalResearch #Renal

At AusBiotech 2026 (Gold Coast, 21–23 October), our team – Tamara Murdock, Global Head of Early Phase, Chantal Elbayeh, Executive Director, Project Delivery; and Belinda Morris, Director, Project Delivery  – will be at Booth #100. Why partner with us in Australia? • CTN scheme – no IND needed, faster start‑up. • 43.5% R&D tax rebate – stretch your budget. • Top‑tier sites and KOLs – we have established networks. • FDA/EMA‑ready data – seamless global regulatory pathway. Whether you are looking for a full‑service partner or specific early phase and late phase support, we have the expertise and local presence to help you succeed. Come talk to us at Booth #100 – let’s explore how we can accelerate your next study. Meet us at AusBiotech International Conference 2026 - Emerald Clinical - emeraldclinical.com/meet-us-… #AusBiotech #CRO #EarlyPhase #ClinicalResearch #Australia #Biotech #EmeraldClinical

What if your oncology trial enrolment strategy could accelerate key milestones by six months or more? In our article, we examine the strategic role of China and Japan in global oncology development. From enrolment modelling and protocol design to evolving regulatory pathways, the discussion highlights why early APAC planning is becoming a competitive advantage for sponsors. For sponsors pursuing accelerated proof-of-concept and global development pathways, timing the APAC decision correctly can make a significant difference. Read the full article and explore the opportunity emeraldclinical.com/insights… #OncologyDevelopment #ClinicalResearch #GlobalClinicalTrials #ChinaOncology #JapanOncology #APACTrials #EmeraldClinical

Developing the next generation of kidney disease therapies starts with the right expertise, investigators, and patient access. In this video, Dr. Vanesa Pomeranz, Senior Medical Monitor, discusses how Emerald Clinical's extensive nephrology expertise, global investigator network, and access to diverse patient populations help sponsors accelerate kidney disease drug development across global markets. Attending ASN Kidney Week? Visit us at Booth #1039 to connect with our renal research experts and learn how we can support your kidney disease clinical development programs. 📍 Meet Dr. Vanesa Pomeranz at Booth #1039 Thursday, October 22 | 10:00 AM - 12:00 PM Friday, October 23 | 10:00 AM - 12:00 PM 👉 Book your meeting here: emeraldclinical.com/meet-us-… #Nephrology #RenalResearch #ClinicalDevelopment #ASNKidneyWeek #ChinaClinicalTrials #EmeraldClinical

We are excited to announce that Emerald Clinical Trials is heading to Denver for ASN Kidney Week 2027. As a full-service CRO with over 25 years of experience, we know what it takes to navigate the complexities of global nephrology studies. Our experience in global IgA Nephropathy (IgAN) studies highlights how we deliver results: by leveraging regional expertise, mitigating operational challenges, and building strong relationships with Key Opinion Leaders. Through this strategic support, we consistently exceed enrollment goals, accelerate database locks, and help our partners secure FDA approvals. Stop by Booth #1039 to see how Emerald Clinical combines deep scientific strategy with global site reach to deliver flawless data quality in complex renal protocols. 👉 Book a dedicated time with our team: emeraldclinical.com/meet-us-… #ASNKidneyWeek #Nephrology #ClinicalTrials #CRO #IgANephropathy #ClinicalResearch #EmeraldClinicalTrials